A World Leader in Therapeutics Targeting Misfolded Proteins and Amyloid Diseases
ProteoTech Overview
- ProteoTech is a world leader in the development of therapeutics targeting misfolded proteins and amyloid diseases.
- Proprietary platform and pipeline of patented disease-modifying drugs for orphan diseases and major CNS diseases.
- Validated by over $16mm in peer-reviewed grant awards (National Institute of Health, National Institute on Aging, Michael J. Fox Foundation for Parkinson's Disease Research)
- Rare orphan disease targets include:
- AL amyloidosis (immunoglobulin light chain), TTR amyloidosis (Transthyretin), Familial Amyloid Polyneuropathy.
- Large market CNS and metabolic disease targets include:
- Alzheimer's Disease, Parkinson's Disease and Type 2 Diabetes.
- Uniquely broad patent estate (over 275 issued patents) including composition of matter patents and other patents pertaining to new therapeutics, diagnostics and misfolded protein screening technologies.
Potential Promising Therapy for Alzheimer's disease
PeptiClere™ (DP-74) is a small peptide compound that has been shown to prevent the formation and accumulation of the soluble and insoluble forms of beta-amyloid found in Alzheimer's victims. It penetrates the blood-brain-barrier intranasally and is being developed as a nasal spray for the treatment of beta-amyloidosis in mild-to-moderate Alzheimer’s disease.
PeptiClere™ (DP-74) is in the late pre-clinical stage of development and we anticipate initiating our IND enabling studies soon.
Contact Us Today
If you have questions or would like to request email updates, please fill out our contact form. We are committed to providing you with a better customer experience and will contact you as soon as possible regarding your requests.